Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New hope for transplant patients with rare cancer: experimental cell therapy enters final testing
Disease control Recruiting nowThis study tests an experimental cell therapy called tabelecleucel for people who develop a rare, aggressive cancer (EBV+ PTLD) after an organ or stem cell transplant and whose cancer did not respond to standard treatment. About 115 participants will receive the therapy to see if…
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New hope for hard-to-treat lung cancer: targeted drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug can shrink tumors. About 345 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
New hope for drug-resistant lung cancer: experimental pill enters human trials
Disease control Recruiting nowThis study tests a new experimental drug called STX-241 in people with advanced non-small cell lung cancer that has stopped responding to current targeted therapies. The drug is designed to reach the brain and attack cancer cells with specific genetic changes. About 171 adults wi…
Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jun 08, 2026 13:09 UTC